Journal: Cancer discovery

Article Title: Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

doi: 10.1158/2159-8290.CD-17-0833

Figure Lengend Snippet: Cytokine heatmaps Day 3 ± anti-PD-1 (a, n=28), anti-CTLA-4 (c, n=24), or anti-PD-1 + anti-CTLA-4 (e, n=24) expressed as log2 fold-change (L2FC) relative to untreated control. Absolute CCL19/CXCL13 levels (pg/mL) observed at Day 3 ± anti-PD-1 (b, n=28), anti-CTLA-4 (d, n=24), or anti-PD-1 + anti-CTLA-4 (f, n=24) (2-sided, paired, t-test, α= 0.05).

Article Snippet: Mouse CCL19 (Abcam, ab100729) and mouse CXCL13 (R&D Systems, MCX130) ELISAs were used according to manufacturer instructions.

Techniques: Control

Journal: Cancer discovery

Article Title: Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

doi: 10.1158/2159-8290.CD-17-0833

Figure Lengend Snippet: a–b, CCL19/CXCL13 mRNA levels from melanoma biopsy samples on anti-PD1 treatment relative to pre-PD-1 (L2FC) by (a) qRT-PCR (n=12) and (b) RNA-seq (n=17 from 10 patients). c, Immune signatures (ssGSEA) in melanoma biopsy specimens (pre- and on-treatment) define immune-infiltrated (Group A, n=10 samples from 4 patients) and immune-poor tumor samples (Group B, n=17 samples from 6 patients). d–e, absolute expression (RPKM) for (d) CCL19 and CXCL13 and (e) their respective receptors, CCR7 and CXCR5 in melanoma biopsy specimens (pre- and on-treatment) in indicated sets of patient samples (group A - immune infiltrated; group B – immune poor by ssGSEA, Fig. 7c). f, Kaplan-Meier survival curve by four-way sorting of CCL19/CXCL13 expression using cutaneous melanoma (SKCM) TCGA data (38) (log-rank Mantel-Cox test). g, immune signatures (ssGSEA) in melanoma biopsy specimens (pre- and on-treatment) in clusters of patients with varying expression of CCL19 and CXCL13 in cutaneous melanoma (SKCM) TCGA. h, Heatmap of Day 3 PDOTS anti-PD1 induced cytokines (L2FC; n=14), ranked by progression-free survival (PFS) and annotated by response to anti-PD-1 therapy (CB, NCB/LTS, or NCB) and timing of sample collection.

Article Snippet: Mouse CCL19 (Abcam, ab100729) and mouse CXCL13 (R&D Systems, MCX130) ELISAs were used according to manufacturer instructions.

Techniques: Quantitative RT-PCR, RNA Sequencing, Expressing

Journal: Journal of Hepatocellular Carcinoma

Article Title: Gut Microbiome and Hepatic Transcriptomic Determinants of HCC Development in Mice with Metabolic Dysfunction-Associated Steatohepatitis

doi: 10.2147/JHC.S485532

Figure Lengend Snippet: Significant association between tumor burden and protein biomarkers CXCL13 and SCF. ( A ) Scatterplot showing correlation between tumor burden (mm 3 ) and serum CXCL13 protein concentration (ng/mL) in the Hep Pten − discovery female mice set. ( B ) Correlation between CXCL13 hepatic expression using RNA sequencing measured in adjusted counts per million (CPM) and serum CXCL13 protein concentration (ng/mL) from the Hep Pten − discovery female mice set. ( C ) Scatterplot showing correlation between tumor burden (mm 3 ) and SCF plasma protein concentration (pg/mL) in the Hep Pten − discovery female mice set. ( D ) Correlation between SCF hepatic expression using RNA sequencing measured in adjusted counts per million (CPM) and SCF plasma protein concentration (pg/mL) from the Hep Pten − discovery female mice set. ( E ) Correlation between tumor burden and serum CXCL13 protein concentration (ng/mL) in the Hep Pten − validation female mice set. ( F ) Correlation between tumor burden and SCF plasma protein concentration (pg/mL) in the Hep Pten − validation female mice set. Spearman correlation was used for all six plots. Spearman correlation p-values and rank correlation coefficients are shown. p<0.05 was considered significant.

Article Snippet: CXCL13 concentration was measured in serum samples using the Quantikine ELISA Mouse CXCL13/BLC/BCA-1 Immunoassay (catalog #MCX130, R&D Systems (bio-techne), Minneapolis) according to manufacturer’s instructions.

Techniques: Protein Concentration, Expressing, RNA Sequencing Assay